Indoleamine 2,3-dioxygenase 1 inhibitors: Molecular pharmacology, structural biology and medicinal chemistry with therapeutic perspectives for Huntington's disease.

Authors

Vishnu Malakar, Chandi C Malakar, Pratap Chand Mali, Nitesh Kumar Poddar

Published in

Biochimica et biophysica acta. Proteins and proteomics. Pages 141177. Sep 18, 2026. Epub Sep 18, 2026.

Abstract

Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder caused by the expansion of the CAG repeat in the HTT (huntingtin) gene. Repeated CAG sequences in the HTT gene lead to the accumulation of a toxic form of the protein within cells that contain it. The kynurenine pathway (KP), which metabolizes the amino acid L-tryptophan, has been implicated in the pathology of HD. The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is a primary component of the KP, producing several neuroactive metabolites, including the neurotoxic metabolite quinolinic acid (QA) and 3-hydroxykynurenine (3-HK). The activity of IDO1 is associated with inflammation, oxidative damage and excitotoxicity. Structures of IDO1 (as represented in the Protein Data Bank under PDB: 2D0T) have enabled the development of inhibitors, with Exiguamine A demonstrating potent IDO1 activity. Though there are challenges with IDO1 selectivity and its penetration into the brain, IDO1 remains a promising candidate and should be further evaluated as a therapeutic target in HD.

PMID:
42759824
Bibliographic data and abstract were imported from PubMed on 19 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.